14.12.2009 • News

GSK Signs $1 Billion Drug Deal with Chroma

Glaxosmithkline announced collaboration with Chroma Therapeutics to develop
macrophage-targeted compounds. Chroma has the potential to receive in excess of $1 billion in total milestone and option payments from GSK. Chroma will receive a significant upfront cash payment and GSK will invest in Chroma's Series D equity financing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read